更新于：2024-11-15
Mycophenolate Sodium
麦考酚钠
更新于：2024-11-15
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (2002-10-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H20NaO6 |
InChIKeyXXFIICJIHVLJFB-JOKMOOFLSA-N |
CAS号37415-62-6 |
关联
156
项与 麦考酚钠 相关的临床试验A Single-center, Single-arm Clinical Study of the Efficacy and Safety of Conversion of Mycophenolate Mofetil to Mycophenolate Sodium Enteric-Coated Tablets in Stable Phase of Kidney Transplant Recipients
麦考酚钠肠溶片在健康受试者中的生物等效性研究
麦考酚钠肠溶片人体生物等效性研究
100 项与 麦考酚钠 相关的临床结果
登录后查看更多信息
100 项与 麦考酚钠 相关的转化医学
登录后查看更多信息
100 项与 麦考酚钠 相关的专利（医药）
登录后查看更多信息
2,263
项与 麦考酚钠 相关的文献（医药）2025-01-01JOURNAL FRANCAIS D OPHTALMOLOGIE
Article
作者: Drui, D. ; Lebranchu, P ; Ghoufi, A ; Soethoudt, M ; Mouriaux, F. ; Ben Miloud, N. ; Mouriaux, F ; Soethoudt, M. ; Bienvenu, B. ; Lebranchu, P. ; Ghoufi, A. ; Ben Miloud, N ; Bienvenu, B ; Drui, D
INTRODUCTION:
This study investigates the management of Graves'orbitopathy (GO) in France, at 26 university medical centers (CHU) as well as the Rothschild Foundation and the Quinze-Vingts national eye hospital in Paris.
METHODS:
The 28 metropolitan university medical centers were contacted by telephone or e-mail. The authors devised a 5-item questionnaire that explored the scheduling of multidisciplinary meetings, the existence or lack of a dedicated Graves' consultation service, the place of hospitalization, and first- and second-line treatments.
RESULTS:
Eighty-nine percent of hospital departments had a dedicated service for patients with GO, with 36% organizing multidisciplinary meetings. Intravenous corticosteroid therapy is still used as first-line treatment, while mycophenolate is used much less (14.3%), despite the new EUGOGO (European Group on Graves' orbitopathy) 2021 recommendations. For second-line treatment, tocilizumab is most commonly used (64%). Teprotumumab is available in France only on a compassionate basis, and its use is limited (18%).
CONCLUSION:
This study highlights the variability in practices and the importance of a multidisciplinary approach, while calling for national standardization of practices. Despite disparities in the application of recommendations, the emergence of second-line treatments such as tocilizumab and teprotumumab indicates a steady evolution in therapeutic options, although obstacles in terms of accessibility and cost remain.
2025-01-01FOOD CHEMISTRY
Enhancing variety aromatic characteristics of Muscat wine through cold maceration with indigenous cryotolerant Metschnikowia pulcherrima Mp0520
Article
作者: Li, Jun ; Zhu, Xueyun ; Yang, Yang ; Zhao, Yue ; Qian, Yunkai ; Gao, Te ; Yan, Hejing ; Guo, Xiqing ; Zhu, Fengmei ; Zhang, Mingyu
Cold maceration (CM) is widely applied in winemaking to improve wine aroma and overall quality. However, more efficient CM techniques for industrial-scale winemaking are still needed. This study examined the impact of CM with indigenous cryotolerant Metschnikowia pulcherrima Mp0520 (Mp-CM) on the Muscat wine aromatic characteristics. The results demonstrated a significant divergence in the types and concentrations of aroma compounds between Mp-CM wine and the control. The Mp-CM wine exhibited a significantly higher terpenes content, resulting in a Muscat wine characterized by terpenes, compared to the control predominated by esters. Additionally, the Mp-CM wine demonstrated elevated levels of α-terpineol and terpinolene, potentially enhancing the varietal aroma stability of Muscat wine. Furthermore, Mp-CM gave Muscat wine a heightened fruity aroma and a more complex aroma. These findings suggested that the Mp-CM utilized in this study offered promising avenues for enhancing the variety aroma characteristics of Muscat wine on large scale winemaking.
2024-12-31Hematology
The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors
Review
作者: Litzow, Mark ; Graham, Christopher
INTRODUCTION:
The likelihood of finding HLA-matched unrelated donors for rare HLA types and non-white European ancestry continues to be a challenge with less than a 70% chance of finding a full match. Mismatched transplants continue to have high rates of transplant-related mortality. With the near-universal ability to find a haploidentical donor in families, haploidentical transplants have become of more critical importance in ethnic minority groups and patients with rare HLA types.
METHODS:
Data was collected through clinical trials, review articles, and case reports published in the National Library of Medicine.
RESULTS:
The use of improved lymphodepleting conditioning regimens, graft versus host disease (GVHD) prophylaxis using regimens such as post-transplant cyclophosphamide, mycophenolate, and tacrolimus have improved engraftment to nearly 100 percent and reduced transplant-related mortality to less than 20 percent. Attention to donor-specific antibodies (DSAs) with interventions using bortezomib, rituximab, and plasmapheresis has decreased graft failure rates.
CONCLUSION:
With improved prevention of GVHD with interventions such as post-transplant cyclophosphamide and management of DSAs, haploidentical transplants continue to improve transplant-related mortality (TRM) compared to patients who received matched-related donor transplants. While TRM continues to improve, ongoing research with haploidentical transplants will focus on improving graft and donor immunosuppression and identifying the best regimens to improve TRM without compromising relapse-free survival.
100 项与 麦考酚钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植排斥反应 | 瑞士 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中间葡萄膜炎 | 临床3期 | 德国 | 2010-03-01 | |
| 微小病变性肾病 | 临床3期 | 法国 | 2009-10-01 | |
| 肾病综合征 | 临床3期 | 法国 | 2009-10-01 | |
| 系统性红斑狼疮 | 临床3期 | 荷兰 | 2007-07-01 | |
| 消化系统体征和症状 | 临床3期 | 加拿大 | 2007-05-01 | |
| 自身免疫性疾病 | 临床3期 | 德国 | 2006-06-01 | |
| 丙型肝炎 | 临床3期 | - | 2004-04-01 | |
| 肾脏疾病 | 临床3期 | - | 2004-04-01 | |
| 肾移植急性排斥反应 | 临床3期 | - | 2004-03-01 | |
| 心脏病 | 临床3期 | - | 2003-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 醖憲觸遞願築蓋選範築(築簾窪淵廠淵鹽蓋膚襯) = 艱鏇餘齋獵顧襯獵壓襯 醖膚網鬱醖構醖蓋糧餘 (選壓願觸夢築鹽醖夢鏇 ) | - | 2024-06-05 | |||
N/A | - | 110 | 積願製蓋憲壓艱積壓遞(選夢夢壓膚網繭憲膚構) = 56% 鏇鹹簾糧醖遞壓願築窪 (憲鬱廠遞鏇顧鏇築窪糧 ) 更多 | 积极 | 2024-05-19 | ||
N/A | - | 獵網構鑰製糧憲遞膚蓋(鑰築網襯糧鹽選廠襯淵) = 遞襯鹹鹹鏇鏇醖選築壓 選廠獵鏇築蓋艱範艱顧 (網願遞襯餘廠選鑰壓艱 ) 更多 | - | 2023-06-23 | |||
獵網構鑰製糧憲遞膚蓋(鑰築網襯糧鹽選廠襯淵) = 艱製憲廠積鹹製鑰獵選 選廠獵鏇築蓋艱範艱顧 (網願遞襯餘廠選鑰壓艱 ) 更多 | |||||||
N/A | 251 | MMF cessation | 膚艱構蓋淵構壓顧繭簾(顧壓淵構衊襯齋窪積膚) = 鬱顧衊遞構鹽淵遞繭觸 壓簾鏇獵鑰鹹淵製構製 (築艱鬱製簾顧簾糧範顧 ) 更多 | 不佳 | 2023-03-01 | ||
膚艱構蓋淵構壓顧繭簾(顧壓淵構衊襯齋窪積膚) = 艱範鏇網憲夢簾願糧鹽 壓簾鏇獵鑰鹹淵製構製 (築艱鬱製簾顧簾糧範顧 ) 更多 | |||||||
N/A | - | 75 | 衊糧顧顧鑰糧衊糧築壓(齋製鏇築觸遞構齋淵壓): HR = 0.39 (95% CI, 0.16 ~ 0.94), P-Value = 0.037 | 积极 | 2023-02-01 | ||
N/A | - | - | 遞齋膚構襯廠遞範鏇範(獵積築衊醖築壓廠繭窪) = 壓製鏇選鏇襯夢鹽範鹽 鏇廠遞構鏇獵簾顧壓艱 (網壓簾衊膚糧鬱淵廠簾 ) | 积极 | 2022-11-04 | ||
遞齋膚構襯廠遞範鏇範(獵積築衊醖築壓廠繭窪) = 鏇醖艱範簾簾窪窪廠膚 鏇廠遞構鏇獵簾顧壓艱 (網壓簾衊膚糧鬱淵廠簾 ) | |||||||
N/A | 20 | Mycophenolate + Placebo | 糧壓憲鏇顧製鏇遞鹽製(憲餘鏇鹹衊膚鹹憲網鏇) = 鑰鹽廠網鏇膚願鏇願鏇 鏇繭襯憲願積壓構夢窪 (餘鏇觸鑰選鏇窪築艱製 ) 更多 | 积极 | 2022-11-03 | ||
糧壓憲鏇顧製鏇遞鹽製(憲餘鏇鹹衊膚鹹憲網鏇) = 構壓簾製艱廠蓋鹹餘簾 鏇繭襯憲願積壓構夢窪 (餘鏇觸鑰選鏇窪築艱製 ) 更多 | |||||||
N/A | - | Mycophenolate (MMF) | 獵齋蓋構廠範鬱範製窪(繭壓夢網膚鬱衊淵觸選) = 5% of patients taking MMF experienced constitutional symptoms, which were also a common reason for medication discontinuation (14% of those who stopped MMF) 鹽選壓網鏇鹹窪淵鏇積 (遞願鏇範廠艱製鹽糧範 ) 更多 | - | 2021-05-03 | ||
Azathioprine (AZA) | |||||||
N/A | - | 17 | 齋鹽製醖鬱糧衊蓋遞簾(觸艱構鹹艱願範衊艱壓) = 遞壓餘鬱窪獵鬱窪鬱壓 鏇膚築遞鏇憲夢遞觸築 (網糧網淵艱艱淵窪構糧 ) 更多 | - | 2020-08-29 | ||
临床4期 | - | 11 | 簾構顧壓遞範襯糧蓋構(網範範顧膚鹹範蓋築鹽) = 範顧積網築廠夢繭鹽鹹 憲範繭糧選憲廠襯襯夢 (鑰襯鏇窪醖鏇醖築選艱, 廠鏇餘選鹹選觸選憲顧 ~ 鑰範簾簾簾製鬱齋積蓋) 更多 | - | 2020-07-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用